מתוך medicontext.co.il
By Will Boggs, MD
WESTPORT, CT (Reuters Health) – T-cell depleted bone marrow transplantation followed by donor lymphocyte infusion can induce graft-versus-myeloma effects in patients with multiple myeloma, according to a report published in the August 15th issue of Blood.
High treatment-related mortality and relapse rates have limited the effectiveness of allogeneic bone marrow transplantation in patients with multiple myeloma, the authors explain.
Hypothesizing that T-cell depletion would reduce transplant-related mortality and that donor lymphocyte infusion (DLI) would foster the graft-versus-myeloma effect, Dr. Edwin Alyea from the Dana-Farber Cancer Institute in Boston and colleagues attempted the combined approach in 24 patients with matched sibling donors and chemotherapy-sensitive multiple myeloma.
All patients engrafted after infusion of the T-cell-depleted bone marrow, the authors report, reaching an absolute neutrophil count above 500 per microliter in a median 12 days and a platelet count above 20,000 per microliter in a median 19 days.
Few patients (2 of 4 who were in complete remission, and 1 of 20 who had evidence of persistent disease at the time of transplant) were in complete remission 6 months after the transplant, the report indicates, though only 1 patient had died within 100 days of transplant.
The 14 patients who received DLI 6 to 9 months after bone marrow transplant fared better as a group, the researchers note. Of 11 patients with persistent disease prior to DLI, 6 developed complete remission and 4 achieved partial remission.
Five patients (36%) remained in complete remission a median 28 months after DLI, the results indicate. Unfortunately, treatment-related toxicity was appreciable. According to the report, 5 patients (21%) died of transplantation-related complications, and 7 of 14 patients receiving DLI developed acute graft-versus-host disease or extensive chronic GVHD.
Nevertheless, six patients showed evidence of graft-versus-myeloma response in the absence of GVHD, the investigators say, and three of these patients achieved complete remission.
Overall 2-year survival after a median follow-up of 2.3 years is 55%, the report indicates, and estimated 2-year, progression-free survival is 30%.
"There is a potent graft-versus-myeloma effect mediated by allogeneic cells," concluded Dr. Alyea told Reuters Health. "Further research in allogeneic transplantation is needed."
"Non-myeloablative transplants, which use much lower doses of chemotherapy at the time of transplant, are currently being explored in patients with myeloma," Dr. Alyea explained. "If this approach is successful, a non-myeloablative transplant may serve as [a] platform from the induction of graft-versus-myeloma effect using donor lymphocyte infusion."
"We are currently using this approach," Dr. Alyea said.
Blood 2001;98:934-939.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!